Risultati della ricerca - I Spicka

Optimizing the model of heating the material in the reheating furnace in metallurgy di I. Špička, M. Heger, O. Zimný, Z. Jančíková, T. Tykva

Testo

Contribution to the thermal properties of selected steels di P. Jonšta, I. Vlčková, L’. Krišták, I. Špička, Z. Jonšta

Testo

LONG-TERM OUTCOMES WITH ISATUXIMAB-CARFILZOMIB-DEXAMETHASONE IN RELAPSED MULTIPLE MYELOMA PATIENTS WITH 1Q21+ STATUS: UPDATED RESULTS FROM THE PHASE 3 IKEMA STUDY di E Crusoe, T Facon, P Moreau, I Spicka, K Suzuki, K Yong, J Mikhael, T Fukao, N Armstrong, T Martin

Testo

ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE VS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (IKEMA): INTERIM ANALYSIS OF A PHASE 3, RANDOMIZED, OPEN-LABE... di A. Maiolino, P. Moreau, M. Dimopoulos, J. Mikhael, K. Yong, M. Capra, T. Facon, R. Hajek, I. Spicka, M. Risse, G. Asset, S. Macé, T. Martin

Testo

Isatuximab plus carfilzomib and dexamethasone vs. carfilzomib and dexamethasone in relapsed/refractory multiple myeloma (ikema): interim analysis of a phase 3, randomized, open-lab... di M. Turgut, P. Moreau, M. Dimopoulos, J. Mikhael, K. Yong, M. Capra, T. Facon, R. Hajek, I. Spicka, M. Risse, G. Asset, S. Macé, T. Martin

Testo

ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA AND SOFT-TISSUE PLASMACYTOMAS: IKEMA SUBGROUP ANALYSIS di A Maiolino, R Hajek, T Jelinek, P Moreau, T Martin, L Pour, G Mikala, A Symeonidis, S Bringhen, A Rawlings, ML Risse, H Vande-Velde, I Spicka

Testo

P34 LIGHTHOUSE (OP-108): MELFLUFEN PLUS DARATUMUMAB (DARA) AND DEXAMETHASONE (DEX) VERSUS DARA IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) REFRACTORY TO AN IMMUNOMODULATORY DRUG... di M Mateos, M Szarejko, J Bila, F Schjesvold, I Spicka, V Maisnar, A Jurczyszyn, Z Grudeva-Popova, R Hajek, G Usenko, M Thuresson, S Norin, S Jarefors, P Richardson, L Pour

Testo

P967: TUMOR BURDEN AS A CRITICAL PROGNOSTIC FACTOR OF PRIMARY EXTRAMEDULLARY DISEASE di M. Vlachová, M. Štork, S. Ševčíková, T. Jelínek, J. Minařík, J. Radocha, P. Krhovská, L. Pospíšilová, I. Špička, J. Straub, P. Pavlíček, A. Jungová, V. Sandecká, V. Maisnar, R. Hájek, L. Pour

Testo

P75 | CURRENT STATUS OF REGISTRY OF MONOCLONAL GAMMOPATHIES - THE CZECH MYELOMA GROUP "REAL WORLD“ DATABASE di V. Maisnar, L. Pour, I. Spicka, J. Minarik, T. Jelinek, A. Jungova, P. Pavlicek, L. Roziakova, J. Radocha, A. Heindorfer, M. Sykora, P. Kessler, L. Stejskal, M. Wrobel, J. Kopeckova, K. Stankova, L. Pospisilova, R. Hajek

Testo

ISATUXIMAB PLUS POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND SOFT-TISSUE PLASMACYTOMAS: ICARIA-MM SUBGROUP ANALYSIS di M.E.Z. Capra, M. Beksac, P.G. Richardson, A. Unal, P. Corradini, S. Delimpasi, Z. Gulbas, G. Mikala, A. Neylon, A. Symeonidis, S. Bringhen, P. Moreau, H.V. Velde, F. Campana, S.L. Guennec, I. Spicka

Testo

P04: DARATUMUMAB PLUS BORTEZOMIB AND DEXAMETHASONE VERSUS BORTEZOMIB AND DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL SURVIVAL RESULTS FROM THE... di P Sonneveld, A Chanan-Khan, K Weisel, AK Nooka, T Masszi, M Beksac, I Spicka, V Hungria, M Munder, MV Mateos, TM Mark, MD Levin, T Ahmadi, X Qin, W Garvin Mayo, X Gai, J Carey, R Carson, A Spencer

Testo

DP111 | POSITRON EMISSION TOMOGRAPHY WITH COMPUTED TOMOGRAPHY AND MINIMAL RESIDUAL DISEASE FOR EFFICACY ASSESSMENT IN TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MYELOMA PATIENTS: IMROZ... di E. Zamagni, T. Facon, M.A. Dimopoulos, X. Leleu, M. Beksac, L. Pour, R. Hajek, Z. Liu, J. Minarik, P. Moreau, J. Romejko-Jarosinska, I. Spicka, T.G. Martin, L. Qiu, C. Sachpekidis, E. Kodas, H. Van De Velde, L. Zhao, R. Orlowski, H. Goldschmidt

Testo

DP114 | ISATUXIMAB, BORTEZOMIB, LENALIDOMIDE, DEXAMETHASONE IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MYELOMA AND PLASMACYTOMAS: IMROZ SUBGROUP ANALYSIS di E. Zamagni, T. Facon, M.A. Dimopoulos, X. Leleu, M. Beksac, L. Pour, R. Hajek, Z. Liu, J. Minarik, P. Moreau, J. Romejko-Jarosinska, I. Spicka, V. Vorobyev, T.G. Martin, L, Qiu, C. Sachpekidis, E. Kodas, Z. Klippel, U. Khan, H. Van De Velde, R. Z. Orlowski, H. Goldschmidt

Testo

P25 | REAL-WORLD OUTCOMES IN NEWLY DIAGNOSED MULTIPLE MYELOMA: EVIDENCE SUPPORTING BORTEZOMIB–LENALIDOMIDE–DEXAMETHASONE AS A PREFERRED REGIMEN WITHOUT ANTI-CD38 ANTIBODIES di A. Jungova, M. Stork, I. Spicka, J. Radocha, J. Minarik, P. Pavlicek, J. Mihalyova, L. Pour, J. Straub, V. Maisnar, T. Pika, T. Dekojova, J. Soukup, T. Popkova, K. Mensikova, F. Sedlák, J. Pospiskova, I. Boichuk, P. Krhovska, T. Stopka, P. Jindra, T. Jelínek, Z. Knechtová, V. Capounova, V. Latal, L. Muronova, A. Heindorfer, J. Ullrychova, M. Sykora, P. Kessler, R. Hajek

Testo

B09 | DARATUMUMAB MONOTHERAPY VERSUS ACTIVE MONITORING IN PATIENTS WITH HIGH-RISK SMOLDERING MULTIPLE MYELOMA: "AQUILA" OUTCOMES BASED ON MAYO 2018/IMWG 2020 RISK STRATIFICATION,... di F. Schjesvold, P.M. Voorhees, M.A. Dimopoulos, Y.C. Cohen, V. Hungria, I. Sandhu, J. Lindsay, R.I. Baker, K. Suzuki, H. Kosugi, M-D. Levin, M. Beksac, K. Stockerl-Goldstein, H. Magen, A. Oriol, G. Mikala, G. Garate, K. Theunissen, I. Spicka, A.K. Mylin, S. Hallam, S. Bringhen, K. Uttervall, B. Pula, A.M. Khan, E. Medvedova, J.C. Ye, A.J. Cowan, Ph. Moreau, M-V. Mateos, H. Goldschmidt, D. Vieyra, A. Raval, L. Sha, L. Li, E. Rousseau, R.M. Dennis, R.L. Carson, S.V. Rajkumar

Testo